Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Corey

Showing results (21-30 of 159) with videos related to

Pageof 16
Sort By:
Nucleic Acid Therapeutics|July 27, 2012
RNA sequencing: platform selection, experimental design, and data interpretationYongjun Chu, David R Corey
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of peptide nucleic acid-peptide conjugatesKunihiro Kaihatsu, David R Corey
Trends in Biotechnology|July 31, 2004
Challenges for RNAi in vivoZain Paroo, David R Corey
Nucleic Acids Research|December 15, 2017
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAsXiulong Shen, David R Corey
Nature Reviews. Drug Discovery|July 23, 2016
Non-coding RNAs as drug targetsMasayuki Matsui, David R Corey
Biochemistry|February 16, 2005
Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell lineKenneth E Huffman, David R Corey
Molecular Biosystems|May 19, 2011
Transcriptional regulation by miRNA mimics that target sequences downstream of gene terminiScott T Younger, David R Corey
Methods in Molecular Biology (Clifton, N.J.)|July 13, 2011
Practical considerations for analyzing antigene RNAs (agRNAs): RNA immunoprecipitation of argonaute proteinJacob C Schwartz, David R Corey
Nucleic Acid Therapeutics|March 26, 2019
Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAsKeith T Gagnon, David R Corey
Nucleic Acid Therapeutics|February 12, 2020
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular DystrophyAnnemieke Aartsma-Rus, David R Corey
Pageof 16

Showing results (21-30 of 159) with videos related to

Sort By:
Pageof 16
Nucleic Acid Therapeutics|July 27, 2012
RNA sequencing: platform selection, experimental design, and data interpretationYongjun Chu, David R Corey
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of peptide nucleic acid-peptide conjugatesKunihiro Kaihatsu, David R Corey
Trends in Biotechnology|July 31, 2004
Challenges for RNAi in vivoZain Paroo, David R Corey
Nucleic Acids Research|December 15, 2017
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAsXiulong Shen, David R Corey
Nature Reviews. Drug Discovery|July 23, 2016
Non-coding RNAs as drug targetsMasayuki Matsui, David R Corey
Biochemistry|February 16, 2005
Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell lineKenneth E Huffman, David R Corey
Molecular Biosystems|May 19, 2011
Transcriptional regulation by miRNA mimics that target sequences downstream of gene terminiScott T Younger, David R Corey
Methods in Molecular Biology (Clifton, N.J.)|July 13, 2011
Practical considerations for analyzing antigene RNAs (agRNAs): RNA immunoprecipitation of argonaute proteinJacob C Schwartz, David R Corey
Nucleic Acid Therapeutics|March 26, 2019
Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAsKeith T Gagnon, David R Corey
Nucleic Acid Therapeutics|February 12, 2020
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular DystrophyAnnemieke Aartsma-Rus, David R Corey
Pageof 16